News › Industry News, News

Novo Nordisk Reveals Plan to Build Mammoth $4.1B Plant in North Carolina to Help Produce Ozempic, Wegovy

June 28, 2024
Bar graph showing growth

GLP-1 heavyweights Eli Lilly and Novo Nordisk are trading haymakers as they scale up production to meet the overwhelming demand for their revolutionary obesity drugs.

A month after Lilly revealed a $5.3 billion investment to increase its manufacturing capacity, Novo has answered.

On Monday, the Danish drugmaker said it will spend $4.1 billion to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina. At 1.4 million square feet, the site will match the combined floor space of Novo’s three current manufacturing sites in the state, the company said.

Read more at Fierce Pharma >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor